追加説明:
This API portfolio covers both Dasatinib monohydrate and Dasatinib anhydrous, positioned in the oncology, molecularly targeted therapeutic category. Dasatinib monohydrate is supported by USDMF No. 23763, US-FDA approval, Zone IVB stability studies and Written Confirmation availability, while Dasatinib anhydrous is backed by USDMF No. 34875 and local GMP certification.
評価とコメントを残す